NCT06799741View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

March 14, 2026

Study Completion Date

March 14, 2026

Conditions
DENV-3 Controlled Human Infection Model
Interventions
DRUG

AV-1 100 mg

"human monoclonal antibody (mAb) intravenous solution~or"

DRUG

AV-1 300 mg

"human monoclonal antibody (mAb) intravenous solution~or"

DRUG

AV-1 900 mg

"human monoclonal antibody (mAb) intravenous solution~or"

DRUG

Placebo

(0.9% saline intravenous solution) 12:2

Trial Locations (3)

21205

Center for Immunization Research (CIR) JHBSPH, Baltimore

21224

Center for Immunization Research Inpatient Unit, Baltimore

05405

UVM Larner College of Medicine Department of MMG, Burlington

Sponsors

Lead Sponsor

AbViro LLC
All Listed Sponsors
lead

AbViro LLC

INDUSTRY

NCT06799741 - A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection | Biotech Hunter | Biotech Hunter